However, using the combined effect of these PSA-SNPs to genetically correct measured PSA did not alter the performance of PSA as a screening tool for prostate cancer (PSA adjusted for the four PSA-SNPs AUC 70.9% compared to unadjusted PSA AUC 70.4% in 415 men who underwent biopsy, p-for-difference not given). Here, KLK3 is linked to prostate carcinoma.